Welcome to our dedicated page for ESSA Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on ESSA Pharma stock.
ESSA Pharma Inc. (NASDAQ: EPIX) is a clinical-stage pharmaceutical company dedicated to advancing novel therapeutics for cancer patients, specifically those battling castration-resistant prostate cancer (CRPC). Founded on cutting-edge research, ESSA Pharma is pioneering the development of small molecule drugs that selectively target the amino-terminal domain of the androgen receptor. This innovative approach aims to overcome known AR-dependent resistance mechanisms in CRPC, potentially offering improved progression-free and overall survival for patients.
ESSA Pharma's flagship candidate, Masofaniten (formerly EPI-7386), is a first-in-class N-terminal domain androgen receptor (AR) inhibitor. Additionally, the company has demonstrated promising results in Phase 1/2 clinical trials that combine Masofaniten with Enzalutamide, another AR inhibitor. These trials have shown deep, durable reductions in prostate-specific antigen (PSA) levels, which are crucial markers in prostate cancer treatment.
Recent data presented at the European Society of Medical Oncology (ESMO) 2023 Congress and the Prostate Cancer Foundation Scientific Retreat reveal that the combination therapy of Masofaniten and Enzalutamide is well-tolerated and effective in reducing PSA levels in patients with metastatic CRPC. The randomized Phase 2 dose expansion study is currently enrolling, with the goal of further elucidating the clinical benefits of this combination therapy.
In recent developments, ESSA Pharma has entered into an ATM Sales Agreement with Jefferies LLC to raise up to US$50 million in capital, ensuring a strong financial runway for ongoing and future projects. The company also reported encouraging financial results for the fiscal year ended September 30, 2023, and the fiscal first quarter of 2024, reflecting a robust cash position expected to fund operations through 2025.
ESSA Pharma's strategy includes exploring additional combinations of Masofaniten with other standard-of-care antiandrogens. The U.S. Food and Drug Administration has granted Fast Track designation to Masofaniten for the treatment of adult male patients with mCRPC resistant to standard-of-care treatments, underscoring the potential importance of this therapy.
For more information, visit the company’s website at www.essapharma.com, or follow them on Twitter and LinkedIn.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company dedicated to prostate cancer therapies, is set to present at the 2022 Jefferies Healthcare Conference in New York City on June 9, 2022, at 3:00 p.m. ET. David R. Parkinson, the President and CEO, along with CFO David S. Wood, will participate in one-on-one meetings during the event. The presentation will follow a fireside chat format and will be accessible via a webcast on the company's website. The archived webcast will be available for 90 days.
ESSA Pharma Inc. (NASDAQ: EPIX) announced its fiscal second-quarter results for the period ending March 31, 2022, reporting a net loss of $10.9 million or $0.25 per share, an improvement from a $13.0 million loss a year ago. The company continues dosing patients in a Phase 1a trial of EPI-7386, a novel androgen receptor inhibitor for metastatic castration-resistant prostate cancer (mCRPC). ESSA's cash reserves stand at $181.0 million, sufficient to fund operations through 2024. Clinical updates on EPI-7386 are anticipated in 2022.
ESSA Pharma Inc. (NASDAQ: EPIX) announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 2:30 p.m. ET. The company's President and CEO, David R. Parkinson, will host one-on-one meetings along with COO Peter Virsik and CFO David S. Wood. The event will be held at the Metro Toronto Convention Centre, offering investors insights into the latest developments in the healthcare sector. A webcast of the presentation will be available on ESSA's website and archived for 90 days.
ESSA Pharma Inc. (NASDAQ: EPIX) has announced the presentation of preclinical data on its ANITAC™ degraders at the 2022 American Association for Cancer Research Annual Meeting. ANITAC degraders target the N-terminal domain of androgen receptors, showing potential to degrade both full length and mutant forms in castration-resistant prostate cancer (CRPC). The data indicates these degraders can inhibit AR-dependent transcription and effectively reduce the viability of AR-dependent prostate cancer cells. Further developments are anticipated this year.
ESSA Pharma Inc. (NASDAQ: EPIX) will present at the virtual Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. ET. David R. Parkinson, President and CEO, alongside COO Peter Virsik and CFO David S. Wood, will engage in one-on-one meetings during the event. ESSA focuses on developing innovative therapies for prostate cancer. A webcast of the presentation will be available on the company's website and archived for 90 days following the event.
ESSA Pharma Inc. (NASDAQ: EPIX) announced the results of its Annual General Meeting of Shareholders held virtually on March 9, 2022. Shareholders set the board of directors at eight members, re-electing all members, including David R. Parkinson and Richard M. Glickman, with high approval percentages. The shareholders also approved the re-appointment of Davidson & Company LLP as auditors and amended the omnibus incentive plan to increase share reserves. Additionally, they supported a non-binding advisory vote on executive compensation frequency for one year.
ESSA Pharma Inc. (EPIX) presented preclinical data on its androgen receptor (AR) N-terminal domain degraders, ANITAC™, at the AACR Annual Meeting 2022. The degraders effectively suppressed AR transcriptional activity and reduced prostate cancer cell viability in castration-resistant prostate cancer (CRPC) models. The data highlighted the ability of ANITAC™ to degrade various forms of AR expressed in CRPC patients. This innovative approach targets a significant challenge in treating advanced prostate cancer, where patients often develop resistance to existing therapies.
ESSA Pharma (NASDAQ: EPIX) updated on its clinical progress and reported financial results for Q1 FY2022, ending December 31, 2021. The company is advancing its lead candidate EPI-7386, with ongoing Phase 1a and Phase 1/2 studies for metastatic castration-resistant prostate cancer. Notable financial results included a net loss of $9.1 million ($0.21 per share), up from $6.5 million the previous year. ESSA's cash reserves stood at $189.2 million, supporting exploration into 2024. Upcoming updates on EPI-7386 are anticipated in the first half of 2022.
ESSA Pharma Inc. (NASDAQ: EPIX) has initiated a Phase 1/2 clinical trial for EPI-7386, a novel N-terminal domain androgen receptor inhibitor, in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC). The trial, beginning with 30 patients, aims to assess safety, tolerability, and preliminary efficacy. The second phase will compare the combination treatment against enzalutamide alone in 120 patients. This study follows EPI-7386's previous Phase 1 trial and reflects ESSA's commitment to advancing prostate cancer therapies.
ESSA Pharma Inc. (NASDAQ: EPIX) reported a corporate update and financial results for the fiscal year ending September 30, 2021. The company posted a net loss of $36.8 million ($0.96 per share), compared to a loss of $23.4 million in 2020. ESSA highlighted progress in its lead candidate EPI-7386 for metastatic castration-resistant prostate cancer, including favorable clinical data and collaborations with major pharmaceutical companies like Janssen, Astellas, and Bayer for upcoming combination studies. Cash reserves of $195 million are anticipated to support operations into 2024.
FAQ
What is the current stock price of ESSA Pharma (EPIX)?
What is the market cap of ESSA Pharma (EPIX)?
What is ESSA Pharma Inc. focused on?
What is Masofaniten?
What recent achievements has ESSA Pharma reported?
What is the significance of the Phase 1/2 clinical trials?
What are the future plans for ESSA Pharma?
What financial position is ESSA Pharma in?
What designations has Masofaniten received from regulatory authorities?
Where can I find more information about ESSA Pharma?
How does Masofaniten work?
What partnerships does ESSA Pharma have?
